Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

Scientists have uncovered a surprising mechanism by which a brain enzyme called OTULIN controls the expression of tau, the ...

Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in ...

But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo's shares fell by nearly 9% at the U.S. market open Monday.

Rutgers neuroscientist Peng Jiang and his neuroscience colleague Mengmeng Jin have made a discovery they say could reshape ...

In people at risk for Alzheimer’s disease, researchers linked minimal to moderate physical activity to a 3-to 7-year delay in cognitive symptoms.

Other noteworthy news in Alzheimer's disease this year included: News about Alzheimer's rose to the forefront in 2025, as the ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

Choose a calm moment, listen first and give the person time to share how they feel. Here are some other tips on how to help a ...